Everolimus versus placebo as a way to reduce risk of recurrence for patients who have had a kidney cancer surgically removed.
Participants may have either a clear cell or non clear cell renal cancer. Bilateral tumors are allowed if they were resected. The participation in this study must start within 84 days of surgery.
Exclusions include, but are not limited to: Prior anti cancer therapy, live vaccine within 7 days, uncontrolled pulmonary disease, severe cardiac disease, cirrhosis or severe liver impairment, HIV and malabsorption syndrome.
“I have an aggressive type of cancer and it was time to take drastic measures…When I heard about the trial from Dr. Hodge, I felt privileged to have this type of care and the chance to help others who may be in my shoes one day.”